AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie just scored an FDA win as its antiviral drug Mavyret received label expansion to treat acute Hepatitis C. The FDA ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now ...